53713-77-2

Upstream product

• 37687-57-3 2-chloro-3-hydroxy-4-methoxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 
• 100-44-7 benzyl chloride 

Downstream Products

• 210105-82-1 3-benzyloxy-2-chloro-4-methoxybenzyl bromide 
• 147317-36-0 pepticinnamin E 
• 147317-36-0 epi-pepticinnamin E 
• 210105-95-6 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine 
• 210105-94-5 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(R)-phenylalanyl-N-methyl-(S)-phenylalanine 
• 210105-90-1 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine allyl ester 
• 210105-89-8 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(R)-phenylalanyl-N-methyl-(S)-phenylalanine allyl ester 
• 210105-92-3 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(S)-phenylalanyl-N-methyl-(S)-phenylalanine-(R)-(piperazine-2,5-dione)methyl ester 
• 210105-91-2 N-benzyloxycarbonyl-(O-benzyloxycarbonyl)-(R)-tyrosyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-(R)-phenylalanyl-N-methyl-(S)-phenylalanine-(R)-(piperazine-2,5-dione)methyl ester 
• 220903-43-5 (R)-N-tert-butyloxycarbonyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 
• 220903-34-4 (S)-N-tert-butyloxycarbonyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 
• 210105-84-3 (R)-N-tert-butyloxycarbonyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 
• 210105-85-4 (S)-N-tert-butyloxycarbonyl-N-methyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine 
• 220903-42-4 (R)-N-tert-butyloxycarbonyl-(3-benzyloxy-2-chloro-4-methoxy)-phenylalanine ethyl ester 

Relevant academic research and scientific papers

Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.

Synthesis and in vitro evaluation of the farnesyltransferase inhibitor pepticinnamin E

The farnesyltransferase inhibitor pepticinnamin E was synthesized and shown to have the S configuration at the central, non-proteinogenic amino acid. Using a recombinant yeast farnesyltransferase the biological activity of the natural product and structur

Synthesis and in vitro evaluation of the Ras farnesyltransferase inhibitor pepticinnamin E

A modularly built bisubstrate inhibitor, the natural product pepticinnamin E (shown on the right) was synthesized for the first time. In the case of in vitro assays it inhibits the enzyme farnesyltransferase with respect to both the peptide substrate and farnesylpyrophosohate (K1 = 30 and 8 μM, respectively). The inhibitory activity is decisively influenced by the central tripeptide unit and the absolute configuration of the non-proteinogenic amino acid incorporated therein.

Synthetic studies on maduropeptin chromophore 2. Synthesis of the madurosamine aryl amide and the C1'-C9' fragments

A retrosynthetic analysis (Scheme 1) of maduropeptin chromophore artifact 1 defined compounds 2 and 3 as required building blocks. The construction of 2 was achieved starting from the 2,5-dimethyl derived aromatic acid 8 and the D-serine derived δ-lactone

Method for improving the absorption and effectiveness of a catecholamine compound

A catecholamine compound is converted to a new mono O-phosphate ester derivative thereof which exhibit improved absorption and effectiveness.